News Breaks |
|
|
| March 11, 2013 |
| 08:32 EDT |  | CBST | Cubist obtains remaining rights to Ceftolozane from Astellas
Cubist Pharmaceuticals and Astellas Pharma announced that they entered into an agreement under which Cubist obtains the rights to ceftolozane in certain Asia-Pacific and Middle East territories from Astellas. With the attainment of these rights, Cubist now owns worldwide rights to develop, manufacture, and commercialize ceftolozane/tazobactam. Ceftolozane, in combination with tazobactam, is currently being studied in two pivotal Phase 3 trials as a potential first-line intravenous therapy for the treatment of complicated intra-abdominal infections and complicated urinary tract infections caused by certain Gram-negative bacteria, including those caused by multi-drug resistant Pseudomonas aeruginosa. Under the terms of the agreement, Astellas will receive an upfront payment of $25M, and sales of ceftolozane/tazobactam made in the newly-obtained territories will be counted towards the existing commercial milestone and royalty terms of the original agreement. Cubist will fund the upfront payment with cash on hand. |
|
|
News For CBST From The Last 14 Days Check below for free stories on CBST the last two weeks. |
|
|
| May 24, 2013 |
| 11:28 EDT |  | CBST | Options with decreasing implied volatility: WCRX P CBST NTI BBY PXP
|
|
| 10:04 EDT |  | CBST | On The Fly: Analyst Downgrade Summary
 Subscribe for More Information |
|
| 07:22 EDT | | CBST | Cubist downgraded at Janney Capital
As previously reported, Janney Capital downgraded Cubist to Neutral from Buy. The firm downgraded shares due to valuation following positive news on the Markman hearings. Price target raised to $55 from $50. |
|
| 06:32 EDT | | CBST | Cubist downgraded to Neutral from Buy at Janney Capital
Subscribe for More Information |
|
| May 23, 2013 |
| 11:37 EDT | | CBST | Options with decreasing implied volatility: WCRX CBST NTI BBY TSLA
|
|
| May 22, 2013 |
| 12:08 EDT | | CBST | Options with decreasing implied volatility: ARNA SGMO NTAP CBST GDI
|
|
| May 21, 2013 |
| 10:00 EDT |  | CBST | On The Fly: Analyst Upgrade Summary
Subscribe for More Information |
|
| 07:17 EDT |  | CBST | Cubist price target raised to $63 from $53 at RBC Capital
Subscribe for More Information |
|
| 06:33 EDT | | CBST | Cubist upgraded to Hold from Sell at Cantor
Subscribe for More Information |
|
| May 20, 2013 |
| 15:56 EDT | | CBST | Cubist move higher attributed to patent construction in suit against Hospira
Subscribe for More Information |
| |
| 15:42 EDT | | CBST | Cubist options active on speculation of a favorable patent ruling
Cubist (CBST) June 55 calls and June 47 puts are active on total call volume of 3K contracts (3K puts). June call option implied volatility is at 37, August is at 40; compared to its 26-week average of 36 according to Track Data. Active option volume suggests traders taking positions for movement on speculation of a favorable patent ruling vs.Hospira (HSP). |
|
| 15:28 EDT |  | CBST | Rumor: Cubist up on speculation of a favorable patent ruling vs.Hospira
|
|
| May 17, 2013 |
| 05:51 EDT | | CBST | Stocks with implied volatility movement; CBST CELG
Subscribe for More Information |
|
| May 16, 2013 |
| 07:29 EDT |  | CBST | Leerink to host a bus tour
Boston Biopharma Bus Tour travels throughout Boston on May 16-17. |
|
| May 15, 2013 |
| 17:46 EDT | | CBST | SAC Capital gives quarterly update on stakes
NEW STAKES: Discovery (DISCA), Liberty Global (LBTYA), Liberty Media (LMCA), Norwegian Cruise Line (NCLH), and Cubist (CBST). INCREASED STAKES: Suncor (SU), EQT Corporation (EQT), Amazon.com (AMZN), Visa (V), and GNC Holdings (GNC). DECREASED STAKES: News Corp. (NWSA), Facebook (FB), Sherwin-Williams (SHW), and Avago (AVGO). LIQUIDATED STAKES: Coach (COH), Dover (DOV), and Virgin Media (VMED), . |
|
| 16:00 EDT | | CBST | Optimer calls active following takeover report
Optimer (OPTR) May and June 17 calls are active on 5,600 contracts (500 puts) according to Track Data. Traders are taking positions for large price movement on Cubist (CBST) offered to buy the company for $20 per share, Reuters says. |
|
| 15:54 EDT | | CBST | Optimer up 12.5%, to $16.03 after Reuters report Cubist offered $20 per share
Subscribe for More Information |
|
| 15:53 EDT | | CBST | Cubist offered to buy Optimer for $20 per share, Reuters says
Subscribe for More Information |
|
| May 13, 2013 |
| 16:53 EDT |  | CBST | Optimer gets bids from AstraZeneca, Cubist, Astellas, Bloomberg says
Optimer (OPTR) has received first round bids from AstraZeneca (AZN), Cubist (CBST), and Astellas, reports Bloomberg, citing people familiar with the matter. Shares of Optimer spiked higher following the report, closing up $1.85, or 14.44%, to $14.66. The report notes the company disclosed almost three months ago it was exploring its strategic options. Reference Link |
|
| 15:55 EDT | | CBST | Optimer gets first round bids from AstraZeneca, Cubist, Bloomberg says
Subscribe for More Information |
| |
|
|
|
|
